Novavax Falls on Report That FDA Wants New Covid Vaccine Trial

Novavax Inc. shares fell after the Wall Street Journal reported that US regulators asked the company to conduct another clinical trial of its Covid vaccine.

The company’s shares dropped as much as 13% on the news Friday. Earlier this week, Novavax said the US Food and Drug Administration was seeking more data as part of a “post-marking commitment,” typically studies on the safety and efficacy of a product after it’s been approved.